| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 2 securities · passive | ||||||
|
AgomAb Therapeutics NV
13G
AGMB · 00860C102
|
5.7% |
5/6/2026
Event 3/31/2026
|
||||
|
Innate Pharma SA
13G/A
45781K105
|
9.1% |
4/29/2025
Event 4/23/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.